Spironolactone prevents hyperkaleamia in transgender teens
According to data, published in the Journal of the Endocrine Society, only 2.2% of transgender adolescents treated with spironolactone developed hyperkalemia after starting initiation therapy.Healio
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Endocrinology | Spironolactone